

CHST15 promotes the proliferation of TE-1 cells via multiple pathways in esophageal cancer

XIN WANG¹, GUOWEI CHENG², TAO ZHANG¹, LEI DENG¹, KUNPENG XU¹, XIN XU¹, WENQING WANG¹, ZONGMEI ZHOU¹, QINFU FENG¹, DONGFU CHEN¹, NAN BI¹ and LUHUA WANG³

¹Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021;

²Department of Radiotherapy, Huanxing Tumor Hospital, Beijing 100023; ³Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, Guangdong 518116, P.R. China

Received May 29, 2019; Accepted October 4, 2019

DOI: 10.3892/or.2019.7395

Abstract. Esophageal squamous cell carcinoma (ESCC) is a common type of esophageal cancer and is prevalent worldwide. Understanding the mechanisms underlying its formation and the search for more effective therapeutic strategies are critical due to the occurrence of chemotherapeutic drug resistance. The aim of the present study was to determine the functional relevance and therapeutic potential of carbohydrate sulfotransferase 15 (CHST15) in ESCC. CHST15 levels were measured in different ESCC cell lines and evaluated in ESCC tissues using tissue chip immunohistochemistry. Cell growth and apoptosis assays, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays, and clonogenic assays were conducted using TE-1 cells and lenti-shCHST15 virus constructs were used to investigate the function of CHST15 in cell proliferation and apoptosis. mRNA microarray analysis was performed to determine the underlying mechanism of CHST15 regulation in TE-1 cell proliferation and apoptosis. The results showed that knockdown of *CHST15* inhibited

TE-1 cell growth and proliferation, but induced cell apoptosis. CHST15 was more frequently detected in ESCC tissue compared with that in normal esophageal tissue. Microarray data analysis indicated that the inhibition of cell proliferation and activation of cell apoptosis in *CHST15*-knockdown cells may be caused by altered CHST15/ILKAP/CCND1 and CHST15/RABL6/PMAIP1 signaling axes, respectively.

Introduction

Esophageal squamous cell carcinoma (ESCC) is a predominant type of esophageal cancer (EC) that is among the leading causes of cancer-related death worldwide (1). China has a very high incidence of ESCC, with more than 100 cases per 100,000 population annually. Studies have shown that certain factors are associated with increased risk of ESCC, such as alcohol and tobacco consumption, genetic mutation, diet and nutrition deficiency (2,3).

Similar to other types of cancer, surgery, chemotherapy, radiotherapy, or a combination of these methods are the main treatments for patients with EC. However, with the increasing incidence of esophageal cancer and the poor 5-year survival rate, more research is needed to investigate the underlying mechanisms underlying EC, to determine how to prevent esophageal cancer development, and to discover more effective treatment strategies for patients with EC.

Studies have identified many prognostic markers related to cell proliferation, cell apoptosis, and metastasis in regards to ESCC, e.g., epidermal growth factor receptor (EGFR) has been reported to be associated with the clinical outcome of many types of cancer, including ESCC. EGFR overexpression is positive in most patients with EC (4). In addition, the level of phosphorylated mammalian target or rapamycin (mTOR), which has an important role in intracellular metabolic and anabolic processes, is associated with the poor prognosis of patients with EC (5). B-cell CLL/Lymphoma 2 (BCL2) family proteins, which are regulators of programmed cell death, such as Fas cell surface death receptor (FAS), BCL2 associated X, apoptosis regulator (BAX) and, especially,

Correspondence to: Dr Luhua Wang, Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 113 Baohe Road, Shenzhen, Guangdong 518116, P.R. China
E-mail: wlhwq@yahoo.com

Dr Nan Bi, Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 17 Panjiayuan Nanli, Chaoyang, Beijing 100021, P.R. China
E-mail: binan_email@163.com

Key words: esophageal squamous cell carcinoma, esophageal cancer, carbohydrate sulfotransferase 15, CHST15, cell proliferation, cell apoptosis, shRNA

BCL2 like 1 (BCL-X) were reported to contribute to ESCC progression (6). Octamer-binding protein 4 (OCT4) and SRY-box 2 (SOX2) also have a high prevalence in ESCC (7). Recently, Cheng *et al* found that solute carrier family 39 member 6 (SLC39A6), a zinc transporter, is associated with ESCC invasiveness (8). Non-coding RNAs have also been identified as essential players in ESCC development (9,10). In most cases, ESCC formation and progression is a complex result of multiple factors, for example, genetic alterations and risk factors of lifestyle. Very recently, Yokoyama *et al* reported that heavy smoking and drinking substantially accelerate the remodeling process of the esophageal epithelium via numerous driver-mutated clones in ESCC development (11). Overall, ESCC is a heterogeneous disease with variable outcomes. However, there are no widely accepted biomarkers for ESCC screening, treatment response, and recurrence prediction.

Carbohydrate sulfotransferase 15 (CHST15), is a type II transmembrane glycoprotein that acts as a sulfotransferase and participates in chondroitin sulfate E (CS-E) biosynthesis (12). It is widely reported that CS-E plays a pivotal role in tumor progression (13). CHST15 is also expressed in B cells as a membrane-integrated glycoprotein disulfide-linked dimer (14). CHST15 was previously reported to be associated with bone marrow-derived mast cell and pulmonary cell metastasis (15,16), as well as tissue fibrosis formation (17-19). In addition, CHST15 correlates with cancer clinical relevance (20-23). For example, Nishimura *et al* evaluated the safety and efficacy of a double-stranded RNA oligonucleotide that specifically represses *CHST15* for use in patients with pancreatic cancer. The results showed that *CHST15* reduction could predict tumor progression and overall survival (20). Ito *et al* indicated significant associations between CHST15 overexpression and disease-free survival and overall survival of patients with pancreatic ductal adenocarcinoma (21).

In the present study, we investigated the correlation between CHST15 expression and proliferation or apoptosis or both in esophageal cancer cells. We further performed gene chip microarray analysis to elucidate the underlying molecular mechanisms in the regulation of esophageal tumor formation or progression by CHST15.

Materials and methods

Construction of a recombinant lentiviral vector. The target sequence (ACAGCATCACAAGTAGGAT) from human *CHST15* mRNA (NM_015892) was selected for the knock-down experiment. The sequence of the control short hairpin RNA (shRNA) was TTCTCCGAACGTGTCACGT. The *CHST15* shRNA and control shRNA oligonucleotides were designed as stem-loop structures and inserted into vector lenti-GV115-EGFP (GeneChem, Shanghai, China) at the *AgeI/EcoRI* sites. Recombinant lentiviruses were produced by co-transfection of the shRNA vector and helper vectors (pHelper1.0 and pHelper2.0) into 293T cells. The medium was replaced with fresh medium 6 h post-transfection. After 48 h post-transfection, cell debris was removed from conditioned medium by centrifugation at 4,000 x g and 4°C for 10 min. The conditioned medium was then filtered through a 0.45- μ m pore-size filter and centrifuged at 4°C and 100,000 x g for 2 h. Lentiviruses particles were resuspended in fresh medium and

stored at -80°C. The lentivirus titer was calculated using a fluorescence titrating assay.

Cell culture and recombinant lentivirus infection. Human ESCC cell lines TE-1, Eca-109, and EC9706 cells were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA) and were cultured in CM2-1 medium comprised of 90% Roswell Park Memorial Institute (RPMI)-1640 (Corning, Inc.), 10% fetal bovine serum (FBS; Ausbian) and 1% penicillin-streptomycin (Beyotime Institute of Biotechnology) at 37°C in a 5% CO₂ incubator. Cells were subjected to mycoplasma testing before experiments. TE-1 cells were plated on 6-well plates and infected with lenti-shCtrl or lenti-shCHST15 at a multiplicity of infection (MOI) of 10. At 72 h post-infection, the cells were observed under a fluorescence microscope (magnification, x200) and harvested to determine knockdown efficiency using quantitative RT-PCR or for other purposes.

Target validation of lenti-shCHST15 in 293T cells and western blotting. 293T cells were transfected with the CHST15 plasmid (GV143-h*CHST15*) using Lipofectamine 2000 (Thermo Fisher Scientific, Inc.) and then infected with lenti-shCtrl or lenti-shCHST15, respectively. Briefly, 293T cells were plated on 24-well plates and transfected with 0.5 μ g of the constructs and 1 μ l of Lipofectamine 2000 when cells reached 80-90% confluence. After 36-48 h of transfection, the cells were rinsed twice with ice-cold phosphate-buffered saline (PBS), collected by scrapping, and lysed using Radioimmunoprecipitation assay (RIPA) buffer (cat. no. P0013B; Beyotime Institute of Biotechnology) supplemented with 1% protease inhibitor cocktail on ice for 10-15 min. Cells were further lysed by sonication at 200 W four times, for 5 sec each time, with a 2-sec interval between pulses. Supernatants were collected after centrifugation at 12,000 x g, at 4°C for 15 min. Protein concentrations were determined using the bicinchoninic acid assay (BCA assay). An amount of 20 μ g protein of each sample were loaded onto 10% SDS-PAGE gel. After electrophoresis, the proteins were transferred to polyvinylidene fluoride (PVDF) membranes. The membranes were blocked in 5% non-fat milk at room temperature for 1 h. The blots were then incubated with anti-Flag antibodies (dilution 1:2,000, cat. no. F1804; Sigma-Aldrich; Merck KGaA) or anti- β -GAPDH antibody (dilution 1:2,000; cat. no. sc-32233; Santa Cruz Biotechnology, Inc.) overnight at 4°C followed by incubation with horseradish peroxidase (HRP)-conjugated secondary antibodies (dilution 1:2,000; cat. no. sc-2005; Santa Cruz Biotechnology, Inc.) for 2 h at room temperature. Blots were visualized using the enhanced chemiluminescent detection method (GE Healthcare).

RNA extraction and cDNA synthesis. Cells were collected and resuspended in 1 ml TRIzol reagent (cat. no. 3101-100; Pufei). RNA was precipitated using isopropanol and dissolved in RNase-free water. The RNA concentration was measured using a NanoDrop 2000 instrument (Thermo Fisher Scientific, Inc.). cDNA for each sample was obtained via a reverse transcription reaction using a Promega M-MLV kit (cat. no. M1705; Promega). All the above steps were performed according to the manufacturer's instruction.

Quantitative real-time reverse transcription PCR (RT-qPCR). The qPCR reaction was set up by mixing primers, SYBR TAQ, and cDNA at the proportion according to the manufacturer's instructions (cat. no. DRR041B, SYBR Master Mixture; Takara). The primer sequences for *GAPDH* were: 5'-TGACTTCAACAGCGACACCCA-3' (forward) and 5'-CACCCTGTTGCTGTAGCCAAA-3' (reverse). The primer sequences for *CHST15* were: 5'-AACACCACCGACCCCTAC-3' (forward) and 5'-TGATGGCGGAGAACTTGA-3' (reverse); the product sizes for *GAPDH* and *CHST15* were 121 and 232 bp, respectively. The qPCR reactions were performed utilizing the Mx3000P qPCR System (Agilent) and at 95°C for 15 sec; followed by 45 cycles at 95°C for 5 sec and 60°C for 30 sec. To compare mRNA levels between different samples, the $2^{-\Delta\Delta C_q}$ method (24) was employed to analyze the data.

Cell growth assay. TE-1 cells infected with lenti-shCtrl or lenti-shCHST15 were plated at 800 cells/well onto a 96-well plate and cultured at 37°C in a 5% CO₂ incubator. Cells with enhanced green fluorescent protein (EGFP) fluorescence in each well were counted daily using a Celigo imaging cytometer (Nexcelom) for 5 days. A cell growth curve was drawn (based on cell numbers) by plotting the numbers of fluorescent-positive cells and time-points. For each cell type, the cell proliferation rates were calculated by dividing the cell number at each time-point by the cell number at day 1.

Cell apoptosis assay. Cell apoptosis was assessed using an Annexin V Apoptosis Detection Kit APC (cat. no. 88-8007; eBioscience). TE-1 cells were seeded on a 6-well plate and infected with lenti-shCtrl or lenti-shCHST15. Four days later, the cells were trypsinized and resuspended in fresh complete medium. The cells were washed with pre-cooled D-Hanks and 1X binding buffer. The cells were suspended in 1X binding buffer, stained with Annexin V-APC, and analyzed using a flow cytometer (Guava easyCyte HT; Millipore). All samples were examined in triplicate.

3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Cell viability after *CHST15* knockdown was measured using an MTT assay. Cells were seeded onto 96-well plates at 2,000 cells/well. At each time point, 20 μ l of 5 mg/ml MTT was added to each well and incubated with the cells for 4 h. Thereafter, the medium was completely removed and 100 μ l of dimethyl sulfoxide (DMSO) was added into each well. After brief shaking, the absorbance at 570 nm of each well was obtained using a microplate reader (M2009PR; Tecan Infinite). Blank wells without cells were included in this experiment. All samples were examined in quintuplicate.

Clonogenic assay. Cells infected with shCtrl or shCHST15 were seeded into 6-well plates at 400–1,000 cells/well. After 10 days of culture, the colonies were washed with PBS and fixed in 4% paraformaldehyde (PFA) for 30–60 min. Colonies were stained with 0.25% crystal violet and counted for analysis. Colonies were counted manually without an instrument. Experiments were performed in triplicate.

Tissue chip immunohistochemistry. The tissue chip used in this experiment included 20 paraffin-embedded sections of

human esophageal squamous cell carcinoma and four adjacent tissue sections. Briefly, the tissue chip was incubated in a 60°C incubator for 30 min. It was then soaked in xylene and serial gradient ethanol from 100–75% for rehydration, incubated with 3% H₂O₂ for 10 min, and stored in distilled water. Antigens in the specimens were retrieved using the sodium citrate (10 mM, pH 6.0) heat-induction method. The tissue chip was blocked in 10% FBS and incubated with anti-CHST15 antibodies (dilution 1:50, cat. no. SAB2701480; Sigma-Aldrich; Merck KGaA) overnight at 4°C. A Vulcan Fast Red Chromogen Kit 2 (Vector Laboratories) was used as the secondary detection system. The slide was then stained with 3,3'-diaminobenzidine (DAB) and hematoxylin. Samples were then dehydrated in gradient ethanol from 75–100% and xylene. The slide was mounted in neutral mounting medium and observed under a microscope (XDS-100; Carl Zeiss). CHST15 expression in each specimen was evaluated based on the percentage of immunopositivity and immunointensity. Each sample was scored based on a range of 0 (non-immunostaining), 1 (weak staining), 2 (moderate staining), 3 (strong staining) based on its immunointensity and scored at the range of 0 (0%), 1 (1–25%), 2 (26–50%), 3 (51–75%), 4 (76–100%) based on its percentage of immunopositivity. The final score of each sample was calculated by multiplying the immunointensity score and the immunopositivity score. Three researchers independently evaluated the chip result to avoid possible biased outcome.

TCGA database and bioinformatic analysis of *CHST15* expression. The *CHST15* gene expression data sets for esophageal squamous cell carcinoma and adjacent normal tissue were obtained from The Cancer Genome Atlas (TCGA) database (<http://cancergenome.nih.gov>), containing a total of 185 carcinoma and 13 normal samples. Comparison of the relative mRNA expression levels between two groups of samples was conducted based on the 'genomic Matrix' file.

Gene microarray and data analysis. Total RNA was isolated from the shCHST15 and control TE-1 cells and processed via hybridization to the GeneChip Primeview Human gene array (901838; Affymetrix) using a GeneChip® 3' IVT Plus Kit (Affymetrix) following manufacturer's protocol. Three biologically independent assays were performed. Washing and staining were performed on the chip using a GeneChip hybridization wash and stain kit. The array was processed using the Affymetrix Genechip Fluidics Station 450 system, after which they were imaged using an Affymetrix Genechip Scanner 3000 7G for subsequent generation of cell intensity (.CEL) files. The raw data were evaluated for quality control using signal histogram analysis, relative signal box plot, Pearson's correlation analysis, and principal component analysis. Qualified data were then used for further analysis. After data cleaning, normalized probe sets were subjected to variance analysis, Bayesian P-value computation, and Benjamini-Hochberg false discovery rate (FDR) for multiple testing correction. Differentially expressed genes based on the comparison of *CHST15* knockdown (KD) and control cells were selected if $|\text{fold change}| > 1.5$ and the FDR was < 0.05 .

Gene Ontology and pathway analysis of differentially expressed genes were conducted using Ingenuity Pathway Analysis (IPA) software (www.qiagen.com/ingenuity, Qiagen)

and Databases for Annotation, Visualization, and Integrated Discovery (<https://david.ncicrf.gov/>), and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways (<https://www.genome.jp/kegg/pathway.html>).

Gene Set Enrichment Analysis (GSEA) was performed using GSEA software v2.2.1 from the Broad Institute (25) to detect if a series of pre-defined biological processes or gene sets were enriched in the gene rank derived from differentially expressed genes between *CHST15*-KD and control cells. Gene sets were judged as significantly enriched if $P < 0.05$ and the false discovery rates (FDR) was < 0.25 in GSEA.

Statistical analysis. Statistical analysis was performed, and graphs were plotted using Microsoft Excel 2013. P-values were determined using two-tailed Student's t-test in at least three biological replicated experiments. Significance was defined as $P < 0.05$. The results are presented as mean $\pm$ standard deviation (SD).

Results

***CHST15* expression in ESCC cell lines and *CHST15* knockdown in TE-1 cells.** We examined *CHST15* expression in three different ESCC cell lines: TE-1, Eca-109, and EC9706. Real-time PCR was performed and the ΔC_q value (*CHST15*-*GAPDH*) of each cell line was calculated for fold change analysis. The data suggested that *CHST15* is expressed in these cells, among which TE-1 has higher *CHST15* expression than Eca-109 and EC9706 (Fig. 1). To investigate the function of *CHST15* in TE-1 cells, a lentivirus *CHST15* shRNA construct was designed and produced. *CHST15*-knockdown (KD) experiments were performed in TE-1 cells. First, we conducted target validation of lenti-*CHST15* shRNA (sh*CHST15*). 293T cells overexpressing *CHST15* were infected with sh*CHST15*. Western blot analysis showed a significantly decreased *CHST15* protein level, which confirmed the targeting of *CHST15* by lenti-sh*CHST15* (Fig. 2A). After 72 h of lenti-sh*CHST15* infection, *CHST15* mRNA expression was significantly reduced by 78% (Fig. 2B) in the sh*CHST15* group compared with that in the Lenti-shCtrl control cells. Fig. 2C shows the TE-1 cells infected with Lenti-sh*CHST15* and Lenti-shCtrl constructs, respectively.

Identification of *CHST15* as a critical gene regulating cell proliferation and apoptosis of TE-1 cells. Three days after sh*CHST15* infection of TE-1 cells, cell proliferation rates were evaluated and compared between sh*CHST15* and shCtrl cells. Cells were counted and images were taken daily from both groups for 5 days. Compared with the substantial increase in cell numbers of the shCtrl cells, the sh*CHST15* KD cells exhibited a significantly reduced proliferation rate (Fig. 3A and B), which indicated that deprivation of *CHST15* inhibited TE-1 cell proliferation. This result was further confirmed using MTT assays, which assessed the viability of sh*CHST15* KD and control cells at different time points (Fig. 3C).

In addition, we determined whether *CHST15* KD would affect the cell colony formation capacity. As expected, the sh*CHST15* group formed fewer colonies compared with the shCtrl cells (12 vs. 140) at 10 days after plating the cells on 6-well plates (Fig. 4). These results revealed that *CHST15* KD




Figure 1. Relative *CHST15* expression in three ESCC cell lines. *CHST15* mRNA levels were measured using RT-qPCR in TE-1, Eca-109 and EC9706 cell lines. *GAPDH* gene expression was used as an internal control. The fold change in *CHST15* expression in the three different cell lines is presented. $n=3$, *** $P < 0.001$ (TE-1 vs. Eca-109, EC9706 vs. Eca-109). *CHST15*, carbohydrate sulfotransferase 15; ESCC, esophageal squamous cell carcinoma.

significantly inhibited the colony formation capacity of the TE-1 cells.

We speculated that cell apoptosis is also altered in the *CHST15* KD cells. At day 4 after infection, sh*CHST15* and shCtrl cells were stained with Annexin V-APC and analyzed by fluorescence activated cell sorting. The data revealed that the percentage of apoptotic cells was significantly higher in the sh*CHST15* infected cells (10%) compared with that in the shCtrl cells (2%) (Fig. 5). Taken together, the results suggested that *CHST15* has a dual role of promoting proliferation and inhibiting apoptosis in TE-1 cells.

Significant *CHST15* overexpression in esophageal squamous cell carcinoma of patients. These *in vitro* data prompted us to hypothesize that *CHST15* may also be expressed in esophageal squamous cell carcinoma and play a possible role in carcinoma formation and progression *in vivo*. To determine the clinical significance of *CHST15* in ESCC samples, *in situ* evaluation of *CHST15* was conducted using an esophageal squamous cell carcinoma tissue chip which included 20 tissue sections from carcinoma specimens and 4 sections from adjacent normal tissue. Patients and sample information are shown in Table I. Immunohistochemistry for *CHST15* in this tissue array is presented in Fig. 6A and B. The immunostaining signal of *CHST15* was found only in the cytoplasm, but not in the cell membrane or nuclei. The *CHST15* expression level in each tumor tissue specimen was evaluated by a score based on the percentage of immunopositivity and immunointensity. Statistical analysis showed that esophageal squamous cell carcinoma presented a 3.5-fold higher *CHST15* level than that noted in the adjacent tissues. The relative *CHST15* mRNA expression level in ESCC samples was calculated by retrieving data sets of 185 ESCC samples and 13 adjacent normal samples from the TCGA database (<http://cancergenome.nih.gov>), which showed that ESCC samples had higher *CHST15* expression (Fig. 6C). Overall, these data indicated that *CHST15* is overexpressed in esophageal squamous cell carcinoma and may have an important role in ESCC formation or progression.




Figure 2. Target validation of lenti-shCHST15 virus in 293T cells and CHST15 knockdown in TE-1 cells. (A) CHST15-overexpressing 293T cells were infected with lenti-shCHST15 or lenti-shCtrl. Cell lysates were subjected to western blotting analysis. (B) CHST15 knockdown in TE-1 cells was confirmed by RT-qPCR. $n=3$, $^{**}P<0.01$. (C) TE-1 cells were infected with lenti-shCHST15 or lenti-shCtrl viruses and imaged by fluorescence microscope at day 3 after infection. Magnification, $\times 200$. CHST15, carbohydrate sulfotransferase 15.

Table I. Characteristics of the patients with ESCC (N=20).

Characteristics	Data
Age (mean $\pm$ SD) in years	56.6 $\pm$ 7.0
Sex, n (%)	
Female	10 (50)
Male	10 (50)
Tumor grade, n (%)	
G1	8 (40)
G2	10 (50)
GX	2 (10)

GX, undetermined grade; ESCC, esophageal squamous cell carcinoma.

Analysis of the mRNA profiles of CHST15 KD and control TE-1 cells. To understand the underlying molecular mechanism of the function of CHST15 in TE-1 cell proliferation and apoptosis, as well as its possible role in ESCC formation and proliferation, we performed genome-wide mRNA microarray analysis to compare the mRNA profiles of the shCHST15 and shCtrl TE-1 group cells. CHST15 KD cells were prepared by lentivirus-shCHST15 infection. Real-time PCR was used to detect the CHST15 knockdown efficiency. The CHST15 mRNA level was reduced by 58.3% compared with that in the control cells. A gene microarray experiment was conducted using shCHST15 and shCtrl cells with three biological repeats. Only qualified RNA samples ($1.7 < A_{260}/A_{280} < 2.2$, RNA Integrity Number ≥ 7.0) were processed by hybridization to the GeneChip Primeview human gene array. We evaluated the raw data from the microarray by signal histogram analysis, relative

signal box plot analysis, Pearson's correlation analysis, and principal component analysis. All of these analyses suggested that the microarray data were suitable for next-step analysis. After data filtering and cleaning, 554 differentially expressed gene transcripts were identified in this gene microarray, among which 188 genes were upregulated and 366 genes were down-regulated in the siCHST15 group compared with the shCtrl control group (Fig. 7A and B).

To identify pathways related to transcriptome changes, we categorized these genes by their associated canonical signaling pathways using Ingenuity Pathway Analysis (IPA) software. Enrichment analysis of differentially expressed genes revealed that the integrin-linked kinase (ILK) and transforming growth factor- β (TGF- β) signaling pathways were inhibited in the CHST15 KD cells, whereas, check point kinase (CHK) proteins in the cell cycle checkpoint control and p53 signaling pathways were activated in the CHST15 KD cells (Fig. 7C). We found that genes encoding proteins involved in the ILK signaling network, such as integrin subunit $\beta 6$ (ITGB6), phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 β (PIK3C2B), protein tyrosine kinase 2 (PTK2), fermitin family member 2 (FERMT2), and cyclin D1 (CCND1), were downregulated in the shCHST15 TE-1 cells according to the dataset.

We also performed a GSEA analysis using the microarray dataset to gain a further insight into the biological processes that CHST15 may be involved in. This analysis was performed to enrich gene sets from differentially expressed genes between CHST15-KD cells and control cells that share common biological function, chromosomal location, and regulation. GSEA revealed that genes associated with cell growth, proliferation, blood vessel morphogenesis, and tissue development were markedly enriched in the dataset of differentially expressed genes (Fig. 8), suggesting that CHST15 may be involved in

Table II. Network of 22 differentially expressed genes identified in the *CHST15* knockdown cells related to cell proliferation and apoptosis processes showing interactions with *CHST15*.

Gene symbol	Fold change	Location	Family
<i>APCDD1</i>	-2.249056649	Plasma membrane	Other
<i>BMP2</i>	2.552303689	Extracellular space	Growth factor
<i>BTG2</i>	-1.801089658	Nucleus	Transcription regulator
<i>CCND1</i>	-1.574172163	Nucleus	Transcription regulator
<i>CHST15</i>	-2.578621457	Plasma membrane	Enzyme
<i>CLU</i>	-1.726946433	Cytoplasm	Other
<i>CREM</i>	1.573881221	Nucleus	Transcription regulator
<i>EEF1A1</i>	-1.600578387	Cytoplasm	Translation regulator
<i>HSPA5</i>	-1.588890827	Cytoplasm	Enzyme
<i>LEPR</i>	1.966722394	Plasma membrane	Transmembrane receptor
<i>MIR17HG</i>	1.509101665	Other	Other
<i>NF1</i>	1.510434197	Cytoplasm	Other
<i>PLAU</i>	1.906482559	Extracellular space	Peptidase
<i>PMAIP1</i>	1.714217298	Cytoplasm	Other
<i>PTH1H</i>	2.256082774	Extracellular space	Other
<i>PTK2</i>	-1.699664502	Cytoplasm	Kinase
<i>SAE1</i>	-1.840426328	Cytoplasm	Enzyme
<i>TGFA</i>	-1.540818218	Extracellular space	Growth factor
<i>TIMP3</i>	-1.590628214	Extracellular space	Other
<i>TPM1</i>	1.923481561	Cytoplasm	Other
<i>USO1</i>	-2.010930656	Cytoplasm	Transporter
<i>WNT5A</i>	-1.526294473	Extracellular space	Cytokine

CHST15, carbohydrate sulfotransferase 15; *APCDD1*, APC down-regulated 1; *BMP2*, bone morphogenetic protein 2; *BTG2*, BTG anti-proliferation factor 2; *CCND1*, cyclin D1; *CLU*, clusterin; *CREM*, cAMP responsive element modulator; *EEF1A1*, eukaryotic translation elongation factor 1 α 1; *HSPA5*, heat shock protein family A (Hsp70) member 5; *LEPR*, leptin receptor; *MIR17HG*, miR-17-92a-1 cluster host gene; *NF1*, neurofibromin 1; *PLAU*, plasminogen activator, urokinase; *PMAIP1*, phorbol-12-myristate-13-acetate-induced protein 1; *PTH1H*, parathyroid hormone like hormone; *PTK2*, protein tyrosine kinase 2; *SAE1*, SUMO1 activating enzyme subunit 1; *TGFA*, transforming growth factor- α ; *TIMP3*, TIMP metalloproteinase inhibitor 3; *TPM1*, tropomyosin 1; *USO1*, USO1 vesicle transport factor; *WNT5A*, Wnt family member 5A.

these biological processes, which are also features of cancer progression.

Differentially expressed genes (DEGs) identified in the *CHST15* knockdown cells were analyzed according to several functional network criteria within IPA. We generated a network with 22 DEGs related to cell proliferation and apoptosis processes (Table II), showing interactions with *CHST15*. This network diagram indicated a molecular mechanism by which *CHST15* regulates the proliferation and apoptosis of TE-1 cells (Fig. 9).

Discussion

Esophageal squamous cell carcinoma (ESCC), a common type of esophageal cancer, is considered a serious malignancy, with a low 5-year overall patient survival rate. Despite the current availability of multiple treatment strategies, the survival rate for ESCC has not significantly improved as many patients present with local advanced disease at the time of diagnosis (3,26). Determining the molecular mechanism underlying ESCC development would be beneficial to identify new diagnostic approaches and therapeutic targets.

In the present study, we showed that carbohydrate sulfotransferase 15 (*CHST15*) is highly expressed in ESCC cell lines and ESCC tissues. We designed lenti-shCHST15 virus constructs and performed *CHST15* knockdown experiments on TE-1 cells. Silencing of *CHST15* inhibited TE-1 cell proliferation and promoted TE-1 cell apoptosis, suggesting that CHST15 contributes to the pathogenesis of ESCC. Tissue array immunostaining and bioinformatic analysis of TCGA data sets of ESCC and adjacent normal tissues both showed that CHST15 is overexpressed in ESCC samples, indicating that CHST15 may play an essential role in mediating the tumorigenicity of ESCC cells.

To gain a deeper insight into the molecular function of CHST15 in ESCC cells, a gene microarray assay was conducted to compare the mRNA profiles of *CHST15*-knockdown cells and control cells. Subsequent Gene Ontology (GO) and KEGG enrichment analysis of the identified differentially expressed genes (DEGs) indicated that CHST15 may be involved in integrin-linked kinase (ILK) and p53 signaling, which regulate cell proliferation and cell apoptosis, respectively. ILKs are important regulators of integrin-mediated signaling. The main function of ILK is to connect integrins to the cytoskeleton. ILK




Figure 3. Inhibition of cell proliferation by *CHST15* knockdown (KD) in TE-1 cells. (A) TE-1 cells were infected with lenti-shCHST15 or lenti-shCtrl and imaged using a Celigo imaging cytometer. (B) A cell proliferation curve was made by calculating the fold change of cell numbers at each time-point. (C) Cell viability of *CHST15* KD and control TE-1 cells was assessed using the MTT assay. n=3, ***P<0.001 (shCHST15 vs. shCtrl). CHST15, carbohydrate sulfotransferase 15.




Figure 4. Reduction in cell colony-formation ability by *CHST15* knockdown. shCHST15 and shCtrl cells were plated in 6-well plates and after 10 days, colonies in each well were counted for analysis. The experiment was performed in triplicate. **P<0.01. CHST15, carbohydrate sulfotransferase 15.

recruits other adaptor molecules into a large complex to regulate actin dynamics and integrin function (27). Overexpression or activation of ILK leads to increased tumor cell proliferation, motility and invasion; thus, ILK may be a promising therapeutic target in many types of cancer (28,29). Downregulated ILK signaling in *CHST15*-knockdown cells may contribute to the inhibition of cell proliferation. P53 is a well-known tumor suppressor that can inhibit cancer progression by provoking

cell growth arrest, by enabling DNA repair, or by advancing cellular death programs (30). In this study, the increased apoptosis of TE-1 cells may be attributable to activated p53 signaling induced by *CHST15* knockdown. The results of GSEA also suggested that CHST15 is significantly associated with cell growth and proliferation processes.

By analyzing DEGs and mapping using IPA software, we identified two possible signaling axes,




Figure 5. Enhanced cell apoptosis by *CHST15*-knockdown (KD) in TE-1 cells. Cell apoptosis was determined by Annexin-V staining and flow cytometry. Increased cell apoptosis was found in *CHST15* KD cells compared with the control cells. The experiment was performed in triplicate. ** $P < 0.01$. *CHST15*, carbohydrate sulfotransferase 15.




Figure 6. *CHST15* overexpression in ESCC tissue specimens. (A) Tissue array consisting of paraffin-embedded sections (a1-d6) of both ESCC and adjacent tissues (shown in the rectangle) were incubated with anti-*CHST15* antibodies and stained with DAB and hematoxylin (original magnification, x40). (B) Higher magnification of representative carcinoma tissue (a2 in the array) and normal adjacent tissue (d3 in the array) with *CHST15* staining (magnification, x400; scale bar, 50 μ m). *CHST15* expression in each specimen was evaluated and scored based on the percentage of immunopositivity and immunointensity. (C) The TCGA database indicated higher *CHST15* mRNA expression in tumor tissues (n=185) when compared with that in normal tissues (n=13). * $P < 0.05$. SD, standard deviation. *CHST15*, carbohydrate sulfotransferase 15.

CHST15/ILK associated serine/threonine phosphatase (ILKAP)/CCND1 and *CHST15*/RAB, member RAS

oncogene family like 6 (RABL6)/phorbol-12-myristate-13-acetate-induced protein 1 (PMAIP1), which regulate ESCC




Figure 7. Differentially expressed genes and pathways in *CHST15*-knockdown (KD) TE-1 cells. (A) Volcano plot of differentially expressed genes. Red dots represent differentially expressed genes, which were selected with $\log_2$ fold change >1.5 and false discovery rate (FDR) <0.05 . (B) Hierarchical clustering heatmap of differentially expressed genes. Rows represent individual genes (188 upregulated genes and 366 downregulated genes in *CHST15*-KD cells). Each column shows the gene expression level of each sample from the shCHST15 group and the shCtrl group. (C) Canonical pathways differentially regulated in *CHST15*-knockdown TE-1 cells were generated by gene enrichment analysis and IPA software. All signaling pathways were ranked by $-\log_{10}$ (P-value). An orange bar indicates an activated pathway. Purple bars represent inhibited pathways. A darker color shade reflects a higher degree of activation or inhibition. CHST15, carbohydrate sulfotransferase 15; IPA, Ingenuity Pathway Analysis.




Figure 8. Identification of CHST15-associated biological processes by GSEA. The analysis showed that genes related to cell growth, cell proliferation, cell development, and blood vessel morphogenesis were significantly enriched in the dataset of differentially expressed genes. CHST15, carbohydrate sulfotransferase 15; GO, Gene Ontology; GSEA, Gene Set Enrichment Analysis.




Figure 9. Gene network describing the possible mechanism of the regulation by CHST15 of cell proliferation and apoptosis as determined by IPA. The key to network is indicated in the rectangular box. IPA, Ingenuity Pathway Analysis.

cell proliferation and apoptosis, respectively. CHST15 is reported to interact with RABL6 (31). RABL6 is a small GTPase belonging to the Ras superfamily, which mainly relays signals from receptors at the cell plasma membrane and modulates many cellular signaling pathways that regulate cell proliferation, differentiation and survival (32). Tang *et al* demonstrated that knockdown of *RABL6* upregulated retinoblastoma 1 (Rb) expression and thus downregulated Rb inhibitory downstream targets, such as cyclin A2, cyclin D1, c-Myc, and cyclin-dependent kinase 2 (33). RABL6 is also a binding partner of PMAIP1, which is a pro-apoptotic member of the BCL2 protein family, but only contains a BH3 domain. PMAIP1 expression was found to activate the mitochondrial apoptotic cascade and induce increased oxidative stress and calcium release, resulting in the activation of apoptosis signal-regulating kinase 1 (ASK1) and its downstream effectors JUN N-terminal kinase (JNK) and mitogen-activated protein kinase 14 (MAPK14, also known as p38) (34). PMAIP1 was also found to regulate p53-induced

apoptosis (35). According to the microarray dataset, PMAIP1 expression was increased in the *CHST15*-knockdown TE-1 cells (Table II). Therefore, CHST15 may promote TE-1 cell apoptosis by interacting with RABL6 and affecting PMAIP1 expression and their subsequent downstream molecules.

CHST15 was also indicated to interact with ILKAP (31), which is a serine/threonine protein phosphatase associated with ILK. It selectively inhibits the ILK-mediated glycogen synthase kinase 3 β (GSK3 β) signaling pathway and further regulates the Wnt signaling pathway by modulating GSK3 β phosphorylation. ILK-mediated inhibition of GSK3 β was found to induce the expression of cyclin D1 (36,37). Cyclin D1 (encoded by *CCND1*) plays a central role in the regulation of proliferation, linking the extracellular signaling environment to cell cycle progression (38). In the *CHST15*-knockdown TE-1 cells, reduced cyclin D1 levels might be the main reason leading to the inhibition of cell proliferation through the CHST15/ILKAP/CCND1 signaling axis. These observations and predictions provide valuable clues for future detailed

investigation of possible CHSR15-associated intracellular signaling pathways.

In summary, the present study investigated the role of CHST15 in cell growth and apoptosis of ESCC and demonstrated the clinical implication of CHST15 in ESCC. CHST15 could be a promising diagnostic marker or therapeutic target for this disease.

Acknowledgements

Not applicable.

Funding

This study was supported by the National Natural Science Foundation of China Grants (21335007) and Fundamental Research Funds for the Central Universities (3332018071).

Availability of data and materials

The microarray dataset in this study is not publicly available since we are using this dataset for further studies. However, it is still available from the corresponding author upon reasonable request.

Authors' contributions

LW and NB designed the study and analyzed the data. XW conducted the majority of experiments and wrote the manuscript. QF, DC and ZZ were involved in construction of the recombinant lentiviral vector. WW and LD conducted the cell growth and apoptosis assays and collected the data. XW, KX, XX, and GC conducted the gene chip microarray experiment and bioinformatic analyses. TZ and XW carried out the tissue chip immunohistochemistry experiment. All authors read and approved the manuscript and agree to be accountable for all aspects of the research in ensuring that the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Ethics approval and consent to participate

The use of human tissue specimen was approved by the Ethics Committee of National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College. The reference number is 19/140-1924. Twenty patients signed consent forms prior to participation.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

- Napier KJ, Scheerer M and Misra S: Esophageal cancer: A Review of epidemiology, pathogenesis, staging workup and treatment modalities. *World J Gastrointest Oncol* 6: 112-120, 2014.
- Domper Arnal MJ, Ferrández Arenas Á and Lanás Arbeloa Á: Esophageal cancer: Risk factors, screening and endoscopic treatment in Western and Eastern countries. *World J Gastroenterol* 21: 7933-7943, 2015.
- Pennathur A, Gibson MK, Jobe BA and Luketich JD: Oesophageal carcinoma. *Lancet* 381: 400-412, 2013.
- Wang J, Yu JM, Jing SW, Guo Y, Wu YJ, Li N, Jiao WP, Wang L and Zhang YJ: Relationship between EGFR over-expression and clinicopathologic characteristics in squamous cell carcinoma of the esophagus: A meta-analysis. *Asian Pac J Cancer Prev* 15: 5889-5893, 2014.
- Hirashima K, Baba Y, Watanabe M, Karashima R, Sato N, Imamura Y, Hiyoshi Y, Nagai Y, Hayashi N, Iyama K and Baba H: Phosphorylated mTOR expression is associated with poor prognosis for patients with esophageal squamous cell carcinoma. *Ann Surg Oncol* 17: 2486-2493, 2010.
- Takayama T, Nagao M, Sawada H, Yamada Y, Emoto K, Fujimoto H, Ueno M, Hirao S and Nakajima Y: Bcl-X expression in esophageal squamous cell carcinoma: Association with tumor progression and prognosis. *J Surg Oncol* 78: 116-123, 2001.
- Nagaraja V and Eslick GD: Forthcoming prognostic markers for esophageal cancer: A systematic review and meta-analysis. *J Gastrointest Oncol* 5: 67-76, 2014.
- Cheng X, Wei L, Huang X, Zheng J, Shao M, Feng T, Li J, Han Y, Tan W, Tan W, *et al*: Solute carrier family 39 member 6 gene promotes aggressiveness of esophageal carcinoma cells by increasing intracellular levels of zinc, activating phosphatidylinositol 3-kinase signaling, and up-regulating genes that regulate metastasis. *Gastroenterology* 152: 1985-1997.e1912, 2017.
- Jang HJ, Lee HS, Burt BM, Lee GK, Yoon KA, Park YY, Sohn BH, Kim SB, Kim MS, Lee JM, *et al*: Integrated genomic analysis of recurrence-associated small non-coding RNAs in oesophageal cancer. *Gut* 66: 215-225, 2017.
- Wang L, Yu X, Zhang Z, Pang L, Xu J, Jiang J, Liang W, Chai Y, Hou J and Li F: Linc-ROR promotes esophageal squamous cell carcinoma progression through the derepression of SOX9. *J Exp Clin Cancer Res* 36: 182, 2017.
- Yokoyama A, Kakiuchi N, Yoshizato T, Nannya Y, Suzuki H, Takeuchi Y, Shiozawa Y, Sato Y, Aoki K, Kim SK, *et al*: Age-related remodelling of oesophageal epithelia by mutated cancer drivers. *Nature* 565: 312-317, 2019.
- Ohtake S, Ito Y, Fukuta M and Habuchi O: Human N-acetylgalactosamine 4-sulfate 6-O-sulfotransferase cDNA is related to human B cell recombination activating gene-associated gene. *J Biol Chem* 276: 43894-43900, 2001.
- Takakura K, Shibasaki Y, Yoneyama H, Fujii M, Hashiguchi T, Ito Z, Kajihara M, Misawa T, Homma S, Ohkusa T and Koido S: Inhibition of cell proliferation and growth of pancreatic cancer by silencing of carbohydrate sulfotransferase 15 in vitro and in a xenograft model. *PLoS One* 10: e0142981, 2015.
- Verkoczy LK, Guinn Ba and Berinstein NL: Characterization of the human B cell RAG-associated gene, hBRAG, as a B cell receptor signal-enhancing glycoprotein dimer that associates with phosphorylated proteins in resting B cells. *J Biol Chem* 275: 20967-20979, 2000.
- Ohtake-Niimi S, Kondo S, Ito T, Kakehi S, Ohta T, Habuchi H, Kimata K and Habuchi O: Mice deficient in N-acetylgalactosamine 4-sulfate 6-O-sulfotransferase are unable to synthesize chondroitin/dermatan sulfate containing N-acetylgalactosamine 4,6-bissulfate residues and exhibit decreased protease activity in bone marrow-derived mast cells. *J Biol Chem* 285: 20793-20805, 2010.
- Mizumoto S, Watanabe M, Yamada S and Sugahara K: Expression of N-acetylgalactosamine 4-sulfate 6-O-sulfotransferase involved in chondroitin sulfate synthesis is responsible for pulmonary metastasis. *Biomed Res Int* 2013: 656319, 2013.
- Sato H, Sagara S, Nakajima N, Akimoto T, Suzuki K, Yoneyama H, Terai S and Yahagi N: Prevention of esophageal stricture after endoscopic submucosal dissection using RNA-based silencing of carbohydrate sulfotransferase 15 in a porcine model. *Endoscopy* 49: 491-497, 2017.
- Suzuki K, Arumugam S, Yokoyama J, Kawauchi Y, Honda Y, Sato H, Aoyagi Y, Terai S, Okazaki K, Suzuki Y, *et al*: Pivotal role of carbohydrate sulfotransferase 15 in fibrosis and mucosal healing in mouse colitis. *PLoS One* 11: e0158967, 2016.
- Kai Y, Tomoda K, Yoneyama H, Kitabatake M, Nakamura A, Ito T, Yoshikawa M and Kimura H: Silencing of carbohydrate sulfotransferase 15 hinders murine pulmonary fibrosis development. *Mol Ther Nucleic Acids* 6: 163-172, 2017.

20. Nishimura M, Matsukawa M, Fujii Y, Matsuda Y, Arai T, Ochiai Y, Itoi T and Yahagi N: Effects of EUS-guided intratumoral injection of oligonucleotide STNM01 on tumor growth, histology, and overall survival in patients with unresectable pancreatic cancer. *Gastrointest Endosc* 87: 1126-1131, 2018.
21. Ito Z, Takakura K, Suka M, Kanai T, Saito R, Fujioka S, Kajihara M, Yanagisawa H, Misawa T, Akiba T, *et al*: Prognostic impact of carbohydrate sulfotransferase 15 in patients with pancreatic ductal adenocarcinoma. *Oncol Lett* 13: 4799-4805, 2017.
22. van der Steen SC, van Tilborg AA, Vallen MJ, Bulten J, van Kuppevelt TH and Massuger LF: Prognostic significance of highly sulfated chondroitin sulfates in ovarian cancer defined by the single chain antibody GD3A11. *Gynecol Oncol* 140: 527-536, 2016.
23. ten Dam GB, van de Westerlo EM, Purushothaman A, Stan RV, Bulten J, Sweep FC, Massuger LF, Sugahara K and van Kuppevelt TH: Antibody GD3G7 selected against embryonic glycosaminoglycans defines chondroitin sulfate-E domains highly up-regulated in ovarian cancer and involved in vascular endothelial growth factor binding. *Am J Pathol* 171: 1324-1333, 2007.
24. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. *Methods* 25: 402-408, 2001.
25. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES and Mesirov JP: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci USA* 102: 15545-15550, 2005.
26. Liu J, Xie X, Zhou C, Peng S, Rao D and Fu J: Which factors are associated with actual 5-year survival of oesophageal squamous cell carcinoma? *Eur J Cardiothorac Surg* 41: e7-e11, 2012.
27. Dedhar S: Cell-substrate interactions and signaling through ILK. *Curr Opin Cell Biol* 12: 250-256, 2000.
28. Hannigan G, Troussard AA and Dedhar S: Integrin-linked kinase: A cancer therapeutic target unique among its ILK. *Nat Rev Cancer* 5: 51-63, 2005.
29. Shirley LA, McCarty S, Yang MC, Saji M, Zhang X, Phay J, Ringel MD and Chen CS: Integrin-linked kinase affects signaling pathways and migration in thyroid cancer cells and is a potential therapeutic target. *Surgery* 159: 163-170, 2016.
30. Stegh AH: Targeting the p53 signaling pathway in cancer therapy-the promises, challenges and perils. *Expert Opin Ther Targets* 16: 67-83, 2012.
31. Hein MY, Hubner NC, Poser I, Cox J, Nagaraj N, Toyoda Y, Gak IA, Weisswange I, Mansfeld J, Buchholz F, *et al*: A human interactome in three quantitative dimensions organized by stoichiometries and abundances. *Cell* 163: 712-723, 2015.
32. Montalbano J, Lui K, Sheikh MS and Huang Y: Identification and characterization of RBEL1 subfamily of GTPases in the Ras superfamily involved in cell growth regulation. *J Biol Chem* 284: 18129-18142, 2009.
33. Tang H, Ji F, Sun J, Xie Y, Xu Y and Yue H: RBEL1 is required for osteosarcoma cell proliferation via inhibiting retinoblastoma 1. *Mol Med Rep* 13: 1275-1280, 2016.
34. Hassan M, Alaoui A, Feyen O, Mirmohammadsadegh A, Essmann F, Tannapfel A, Gulbins E, Schulze-Osthoff K and Hengge UR: The BH3-only member Noxa causes apoptosis in melanoma cells by multiple pathways. *Oncogene* 27: 4557-4568, 2008.
35. Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, Yamashita T, Tokino T, Taniguchi T and Tanaka N: Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. *Science* 288: 1053-1058, 2000.
36. Kumar AS, Naruszewicz I, Wang P, Leung-Hagesteijn C and Hannigan GE: ILKAP regulates ILK signaling and inhibits anchorage-independent growth. *Oncogene* 23: 3454-3461, 2004.
37. Leung-Hagesteijn C, Mahendra A, Naruszewicz I and Hannigan GE: Modulation of integrin signal transduction by ILKAP, a protein phosphatase 2C associating with the integrin-linked kinase, ILK1. *EMBO J* 20: 2160-2170, 2001.
38. Yang K, Hitomi M and Stacey DW: Variations in cyclin D1 levels through the cell cycle determine the proliferative fate of a cell. *Cell Div* 1: 32, 2006.



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.